BRISTOL MYERS SQUIBB CO Form 8-K May 10, 2005

# **UNITED STATES**

# SECURITIES AND EXCHANGE COMMISSION

FORM 8-K

### **CURRENT REPORT**

Pursuant to Section 13 OR 15(d) of The Securities Exchange Act Of 1934

Date of Report (Date of earliest event reported): May 9, 2005

# **BRISTOL-MYERS SQUIBB COMPANY**

 $(Exact\ Name\ of\ Registrant\ as\ Specified\ in\ its\ Charter)$ 

Delaware (State or Other Jurisdiction

1-1136 (Commission File Number) 22-079-0350 (IRS Employer

of Incorporation)

**Identification Number)** 

345 Park Avenue

New York, NY, 10154

(Address of Principal Executive Office)

Registrant s telephone number, including area code: (212) 546-4000

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (*see* General Instruction A.2. below):

- " Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- " Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- " Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- " Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

#### Item 8.01. Other Events.

On May 9, 2005, Bristol-Myers Squibb Company issued a press release announcing it filed with the United States Securities and Exchange Commission its 2005 first quarter Form 10-Q that revises certain financial information relating to additional litigation reserves recorded after the company s first quarter financial results were announced on April 28, 2005. In the Form 10-Q, pre-tax earnings were reduced by \$110 million reflecting additional litigation reserves for previously disclosed matters recorded after the issuance of first quarter financial results. The previously disclosed matters are wholesaler inventory and certain other accounting matters. Total reserves for these matters reported in the Form 10-Q are currently \$140 million. A copy of the press release is attached to this report as Exhibit 99.1.

#### **Item 9.01 Financial Statement and Exhibits**

- (c) Exhibits
- 99.1 Press release, dated May 9, 2005

#### **SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Bristol-Myers Squibb Company

Date: May 9, 2005

By: /s/ Sandra Leung

Name: Sandra Leung Title: Secretary

### EXHIBIT INDEX

Exhibit No.	Description
99.1	Press Release, dated May 9, 2005